Drug Development Risk Register
This is a practical guide to building a risk register for a drug development project — the living log of risks with scores, owners and responses, adapted to the realities of developing a pharmaceutical product through regulatory stages.
What a Risk Register is
A risk register is the living log of risks with scores, owners and responses. For the full concept and how it works in general, see Risk Register. On a drug development project it plays the same role, tuned to this kind of work.
Why it matters for a Drug Development project
Drug Development projects live or die on developing a pharmaceutical product through regulatory stages. A well-built risk register gives the team a shared, explicit reference for exactly that — reducing ambiguity, aligning stakeholders, and making problems visible early enough to act. Skipping it, or doing it generically, is how drug development projects drift into avoidable delay and cost.
What to include
- Risk description and category
- Probability and impact
- Risk score
- Owner
- Response and trigger
Drug Development-specific considerations
Tailor the risk register to the risks that most often derail drug development projects:
- Regulatory approval delays
- Trial/validation failures
- Strict GxP compliance
Example
On a real drug development project, the risk register would be shaped by developing a pharmaceutical product through regulatory stages. In particular, it should explicitly account for the project’s biggest risks — regulatory approval delays, trial/validation failures, strict GxP compliance — rather than treating them as afterthoughts.